Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells

British Journal of Cancer

Volumn 98, Issue 6, 2008, Pages 1132-1140

  Akinmade, D ^a,b   Talukder, A H ^c   Zhang, Y ^a,b   Luo, W M ^b   Kumar, R ^c   Hamburger, A W ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Ebp1; PA2G4; PAK1; Phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3 BINDING PROTEIN 1; NEU DIFFERENTIATION FACTOR; P21 ACTIVATED KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL PROLIFERATION; HUMANS; MUTATION; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTEIN BINDING; RNA-BINDING PROTEINS; SUBSTRATE SPECIFICITY; TAMOXIFEN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 40849135855     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604261     Document Type: Article

References (39)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R (1998) Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273: 28238-28246
2. Ahn JY, Liu X, Liu Z, Pereira L, Cheng D, Peng J, Wade PA, Hamburger AW, Ye K (2006) Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J 25: 2083-2095
3. Akinmade D, Lee M, Zhang Y, Hamburger AW (2007) Ebp1-mediated inhibition of cell growth requires serine 363 phosphorylation. Int J Oncol 31: 851-858
4. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R (2004) p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279: 1422-1428
5. Barnes CJ, Vadlamudi RK, Mishra SK, Jacobson RH, Li F, Kumar R (2003a) Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol 10: 622-628
6. Barnes CJ, Vadlamudi RK, Mishra SK, Jacobson RH, Li F, Kumar R (2003b) Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol 10: 622-628
7. Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway III KL (2002) An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci USA 99: 2866-2871
8. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF, Hynes NE (2003a) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938
9. Holbro T, Civenni G, Hynes NE (2003b) The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110
10. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98: 671-680
11. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
12. Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM (2003) Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22: 8178-8186
13. Johnson DG, Ohtani K, Nevins JR (1994) Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8: 1514-1525
14. Johnston SR (2006) Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 12: 1061s-1068s
15. King CC, Sanders LC, Bokoch GM (2000) In vivo activity of wild-type and mutant PAKs. Methods Enzymol 325: 315-327
16. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193-9197
17. Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6: 459-471
18. Kumar R, Vadlamudi RK (2002) Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol 193: 133-144
19. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC (1992) Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121
20. Lessor TJ, Hamburger AW (2001) Regulation of the ErbB3 binding protein Ebp1 by protein kinase C. Mol Cell Endocrinol 175: 185-191
21. Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW (2000) Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol 183: 321-329
22. Liu Z, Ahn JY, Liu X, Ye K (2006) Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci USA 103: 10917-10922
23. Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Matthews S, Goodfellow IG, Curry S (2007) Structural insights into the transcriptional and translational roles of Ebp1. EMBO J 26(17): 3936-3944
24. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y (1996a) Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271: 19029-19032
25. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996b) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467
26. Qiu XB, Goldberg AL (2002) Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci USA 99: 14843-14848
27. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R (2006) P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66: 1694-1701
28. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
30. Squatrito M, Mancino M, Donzelli M, Areces LB, Draetta GF (2004) EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23: 4454-4465
31. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103: 1770-1777
32. Xia X, Cheng A, Lessor T, Zhang Y, Hamburger AW (2001) Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol 187: 209-217
33. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4): S3-S8
34. Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW (2000) Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer 82: 683-690
35. Zhang Y, Akinmade D, Hamburger AW (2005) The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Res 33: 6024-6033
36. Zhang Y, Hamburger AW (2004) Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription. J Biol Chem 279: 26126-26133
37. Zhang Y, Hamburger AW (2005) Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Br J Cancer 92: 140-146
38. Zhang YX, Fondell JD, Wang QB, Xia XM, Cheng AW, Lu ML, Hamburger AW (2002) Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21: 5609-5618
39. Zhang YX, Woodford N, Xia XM, Hamburger AW (2003) Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res 31: 2168-2177